This study revealed for the first time that there were changes in the albumin binding activities in NAFLD, viral hepatitis, and liver cirrhosis patients; and our findings suggested that albumin binding activity may be an early marker for liver function during disease development comparing to other liver parameters. Here, ALB is linked to metabolic dysfunction-associated steatotic liver disease.